Unlocking best-in-class
therapies for patients with
auto-immune disorders


We are what we do

Zura Bio Limited is a clinical-stage biotechnology company advancing immunology assets into Phase 2 development programs, including ZB-168 and Torudokimab. ZB-168 is an anti IL7R α inhibitor that has the potential to impact diseases driven by IL7 and TSLP biological pathways. Zura aims to develop a portfolio of therapeutic indications for ZB-168 which build on existing Phase 1b data in Type 1 Diabetes demonstrating a favorable safety profile and strong biological rationale. Torudokimab is a fully human, high affinity monoclonal antibody that neutralizes IL33 and is currently at the Phase 2 clinical development stage.


Zura Bio is founded and led by an entrepreneurial management team with broad and deep experience in the pharmaceutical industry and a proven track record of successfully identifying and developing innovative medicines that advance patient care and improve their well-being

Here’s our who’s who


Someit Sidhu, M.D.

Chief Executive Officer and Director

Chris Cabell, M.D.

Chief Medical Officer and Head of R&D

Gary Whale, Ph.D.

Chief Technology Officer

Kim Davis

Chief Legal Officer

Kiran Nistala, M.B.B.S., Ph.D.

Executive Vice President

Michael Howell, Ph.D.

Chief Scientific Officer and Head of Translational Science

Verender Badial

Chief Financial Officer


Amit Munshi


Arnout Ploos van Amstel

Independent Director

Jen Jarrett

Independent Director

Neil Graham, M.D.

Independent Director

Parvinder Thiara

Independent Director

Sandeep Kulkarni, M.D.

Independent Director

Someit Sidhu, M.D.

Chief Executive Officer and Director

Steve Schoch

Independent Director